retatrutide type 2 diabetes trial results 2024 Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase clinical retatrutide phase 2 trial type

Pancreatitis is incredibly painful and can be deadly, lead author Leslie Iverson, PA-C, cardiovascular prevention and research clinician at Intermountain Health, said in a press release

Retatrutide: Designed to Last One of the newest GLP-1 medications in development is retatrutide , a triple agonist (GLP-1, GIP, and glucagon receptors) designed with an approximate 6-day half-life , thanks to advanced pharmaceutical engineering

Monitoring lipid levels helps assess overall cardiovascular health, particularly important given that many patients with type 2 diabetes have concurrent dyslipidemia

Injecting a GLP-1 weekly can serve as a physical reminder to maintain healthy habits

It completed Phase 2 trials in obesity [3] and type 2 diabetes [4] and moved into a Phase 3 program (TRIUMPH)

Mechanism of BP Reduction Multiple factors contribute to retatrutide's blood pressure effects: Weight Loss Effect: Losing 28.7% of body weight reduces cardiac workload